Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279741 | 0.85 | ALOX15 (0.47) | RAB9ANPC1TAS1R3TAS1R1CYP1A2 | |
| SCHEMBL933081 | 0.85 | ALOX15 (0.47) | RAB9ANPC1TAS1R3TAS1R1CYP1A2 | |
| SCHEMBL4308571 | 0.83 | CES2 (0.42) | RAB9ANPC1CES2CES1CYP1A2 | |
| SCHEMBL13082597 | 0.80 | TSHR (0.63) | RAB9ACES2CES1TAS1R3TAS1R1 | |
| SCHEMBL4783841 | 0.80 | RAB9A (0.46) | RAB9ANPC1CES2CES1CYP1A2 | |
| SCHEMBL4120055 | 0.80 | CES2 (0.66) | RAB9ANPC1CES2CES1CYP1A2 | |
| SCHEMBL31331522 | 0.78 | CYP1A2 (0.71) | RAB9ANPC1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL6670439 | 0.78 | PARP1 (0.68) | NPC1CES2CES1CYP1A2HPGD | |
| SCHEMBL31164288 | 0.76 | ALDH1A1 (0.62) | RAB9ATAS1R3TAS1R1CYP1A2CYP2C19 | |
| SCHEMBL3535173 | 0.76 | AURKA (0.47) | RAB9ANPC1CES2CES1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700602-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700602-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700602-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1756087-B1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH CORP (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090093498-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093498-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093498-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| US-7482349-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482349-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482349-B2 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of β-secretase | WYETH (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1756087-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | Wyeth (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006009653-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009653-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | RAB9A 1424/4885NPC1 57/4885CES2 1191/4885 |
| US-20090093498-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | BACE1, BACE2, APP | RAB9A 2565/4885NPC1 710/4885CES2 3023/4885 |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | BACE1, BACE2, APP | RAB9A 2565/4885NPC1 710/4885CES2 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.